Funding for this research was provided by:
Received: 30 March 2021
Accepted: 5 October 2021
First Online: 12 November 2021
: The protocol was approved by Ethical and Independent Review Services (approval number 18186). The clinical sites were approved by Ethical and Independent Review Services (approval number 18186–01) and University of Cincinnati institutional review board (approval number 2019–0115). The study was conducted in accordance with the ethical standards of the Declaration of Helsinki (1964) and its subsequent amendments, and with International Council for Harmonisation Good Clinical Practices. All participants gave written informed consent to participate and permitted audio-recording of the interviews.
: Not applicable.
: B.M.C. is a former employee of Evidera, which was paid by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson (the sponsor), to conduct the study. L.S. and L.K. are current employees of Evidera. E.W.D. is a former employee of Actelion Pharmaceuticals Ltd. A.B. is a current employee of Actelion Pharmaceuticals Ltd and holds shares in Johnson & Johnson. R.P.B. has been a consultant for and received research grants from Actelion Pharmaceuticals Ltd.